Advances in inducing adaptive immunity using cell-based cancer vaccines: Clinical applications in pancreatic cancer.
World J Gastroenterol
; 22(18): 4446-58, 2016 May 14.
Article
em En
| MEDLINE
| ID: mdl-27182156
ABSTRACT
The incidence of pancreatic ductal adenocarcinoma (PDA) is on the rise, and the prognosis is extremely poor because PDA is highly aggressive and notoriously difficult to treat. Although gemcitabine- or 5-fluorouracil-based chemotherapy is typically offered as a standard of care, most patients do not survive longer than 1 year. Therefore, the development of alternative therapeutic approaches for patients with PDA is imperative. As PDA cells express numerous tumor-associated antigens that are suitable vaccine targets, one promising treatment approach is cancer vaccines. During the last few decades, cell-based cancer vaccines have offered encouraging results in preclinical studies. Cell-based cancer vaccines are mainly generated by presenting whole tumor cells or dendritic cells to cells of the immune system. In particular, several clinical trials have explored cell-based cancer vaccines as a promising therapeutic approach for patients with PDA. Moreover, chemotherapy and cancer vaccines can synergize to result in increased efficacies in patients with PDA. In this review, we will discuss both the effect of cell-based cancer vaccines and advances in terms of future strategies of cancer vaccines for the treatment of PDA patients.
Palavras-chave
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Neoplasias Pancreáticas
/
Células Dendríticas
/
Terapia Genética
/
Transplante de Células
/
Vacinas Anticâncer
/
Carcinoma Ductal Pancreático
/
Imunidade Adaptativa
/
Microambiente Tumoral
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article